Astellas' fezolinetant reduces frequency and severity of VMS

Japanese pharma major Astellas (TYO;4503) today presented 24-week results from the Phase IIIb DAYLIGHT clinical trial examining the efficacy and safety of fezolinetant, at the 15th Congress of the European Society of Gynecology (ESG) in Amsterdam, Netherlands.

Fezolinant is an investigational oral, non-hormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) - hot flashes and/or night sweats - associated with menopause in women considered unsuitable for hormone therapy.

In May this year, the US Food and Drug Administration finally approved Veozah (fezolinetant) for the treatment of moderate to severe vasomotor symptoms. The US regulator has previously issued a delay on its review of the marketing application.